Brazil spends R$3 billion per year on diseases transmitted by the aedes aegypti mosquito. This is what a study that is being published, exclusively, by SBT Brasil reveals.
Dengue, zika, chikungunya and yellow fever, diseases transmitted by mosquitoes, are responsible for 86.7% of absences from work, according to a survey by the Federation of Industries of the State of Rio de Janeiro. In the last two years alone, there have been more than 15 million cases. Each year, the loss for companies exceeds R$844 million, with total expenditure reaching R$3 billion.
Fever, headache, nausea, nausea, red spots on the skin, bleeding, abdominal pain and vomiting are some symptoms of dengue.
More than 1 million Brazilians are infected with dengue every year, according to the Ministry of Health. The fight against mosquitoes is part of measures to reduce this rate, but experts believe in the development of vaccines to prevent serious symptoms. A 100% national immunizer is already in the final stages of approval at the Butantan Institute.
The vaccine, with the attenuated virus, induces the production of antibodies without causing the disease. 17 thousand volunteers from across the country participate in the tests in 16 research centers.
“In volunteers who took the vaccine, they had 80% fewer cases of symptomatic dengue than in volunteers who received placebo”, says Fernanda Boulos, medical director of the Butantan Institute.
The vaccine should be ready next year, and to enter the National Immunization Program (PNI) it must be approved by the National Health Surveillance Agency (Anvisa).
In March, Anvisa released QDENGA, developed by a Japanese laboratory. The two-dose vaccine costs R$800.
“It has demonstrated this really very significant effectiveness of 80% reduction in cases of symptomatic dengue and 90% reduction in hospitalization cases. We have been working with the government to include the vaccine in the Unified Health System as quickly as possible”, says Vivian Kiran Lee.
Brazil spends R$3 billion per year on diseases transmitted by the aedes aegypti mosquito. This is what a study that is being published, exclusively, by SBT Brasil reveals.
Dengue, zika, chikungunya and yellow fever, diseases transmitted by mosquitoes, are responsible for 86.7% of absences from work, according to a survey by the Federation of Industries of the State of Rio de Janeiro. In the last two years alone, there have been more than 15 million cases. Each year, the loss for companies exceeds R$844 million, with total expenditure reaching R$3 billion.
Fever, headache, nausea, nausea, red spots on the skin, bleeding, abdominal pain and vomiting are some symptoms of dengue.
More than 1 million Brazilians are infected with dengue every year, according to the Ministry of Health. The fight against mosquitoes is part of measures to reduce this rate, but experts believe in the development of vaccines to prevent serious symptoms. A 100% national immunizer is already in the final stages of approval at the Butantan Institute.
The vaccine, with the attenuated virus, induces the production of antibodies without causing the disease. 17 thousand volunteers from across the country participate in the tests in 16 research centers.
“In volunteers who took the vaccine, they had 80% fewer cases of symptomatic dengue than in volunteers who received placebo”, says Fernanda Boulos, medical director of the Butantan Institute.
The vaccine should be ready next year, and to enter the National Immunization Program (PNI) it must be approved by the National Health Surveillance Agency (Anvisa).
In March, Anvisa released QDENGA, developed by a Japanese laboratory. The two-dose vaccine costs R$800.
“It has demonstrated this really very significant effectiveness of 80% reduction in cases of symptomatic dengue and 90% reduction in hospitalization cases. We have been working with the government to include the vaccine in the Unified Health System as quickly as possible”, says Vivian Kiran Lee.
